Literature DB >> 21126724

A case of recurrent benign lymphocytic (Mollaret's) meningitis and review of the literature.

P J Poulikakos1, E E Sergi, A S Margaritis, A G Kioumourtzis, G D Kanellopoulos, P K Mallios, D J Dimitrakis, D J Poulikakos, A A Aspiotis, A D Deliousis, C P Flevaris, A K Zacharof.   

Abstract

Mollaret's meningitis is a rare form of benign recurrent aseptic meningitis first described in 1944. We report a case of Mollaret's meningitis due to Herpes Simplex Virus type 2 (HSV2), diagnosed with Polymerase Chain Reaction (PCR) implementation in the Cerebrospinal fluid (CSF) of the patient and treated successfully with acyclovir. To our knowledge, this is the first case of Mollaret's meningitis reported in Greece. We reviewed the literature since PCR has become widely available. Herpes Simplex Virus type 2 has been the most commonly identified causative agent of Mollaret's meningitis.
Copyright © 2010 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21126724     DOI: 10.1016/j.jiph.2010.09.006

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  4 in total

Review 1.  Recurrent Meningitis.

Authors:  Jon Rosenberg; Benjamin T Galen
Journal:  Curr Pain Headache Rep       Date:  2017-07

2.  Benign Recurrent Aseptic Meningitis (Mollaret's Meningitis) in an Elderly Male: A Case Report.

Authors:  Swati Chand; Sangharsha Thapa; Khusal Gautam; Anu Radha Twayana; Maryrose R Laguio-Vila; Tarek Elsourbagy
Journal:  JNMA J Nepal Med Assoc       Date:  2021-09-11       Impact factor: 0.556

3.  Mollaret's Meningitis: A Rare Entity.

Authors:  Abhinav Sehgal; Esana Pokhrel; Walter R Castro; Christopher J Haas
Journal:  Cureus       Date:  2021-05-26

Review 4.  Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.

Authors:  Paula A Suazo; Eduardo I Tognarelli; Alexis M Kalergis; Pablo A González
Journal:  Med Microbiol Immunol       Date:  2014-09-11       Impact factor: 3.402

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.